drugset / Trial / NCT00125359
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Phase 2
Completed
42 enrolled
Konstantin Dragnev
Genentech, Inc. · collabLigand Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Timeline
- Start
- 2005-08
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 400 mg/m2 | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |